Trifecta Capital Advisors’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.8K Sell
175
-1,210
-87% -$70.8K ﹤0.01% 229
2026
Q2
$53.1K Buy
1,385
+1,175
+560% +$30.8K 0.01% 187
2026
Q1
$4.46K Hold
210
– – ﹤0.01% 247
2025
Q4
$3.43K Sell
210
-17,130
-99% -$259K ﹤0.01% 249
2025
Q3
$203K Sell
17,340
-11,860
-41% -$155K 0.03% 106
2025
Q2
$338K Buy
+29,200
New +$266K 0.06% 82

Other funds holding TXG

Trifecta Capital Advisors's TXG Position: Q3 2026 in Review

Trifecta Capital Advisors reduced its 10x Genomics (TXG) stake by 87% in Q3 2026, selling an estimated $70.8K and leaving 175 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #229.

Trifecta Capital Advisors first reported a position in TXG in Q2 2025 and has held it in 6 quarters since. The position peaked at $338K in Q2 2025. 494 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Trifecta Capital Advisors held 175 shares of 10x Genomics worth $15.8K as of Q3 2026.
  • Trifecta Capital Advisors sold 1,210 10x Genomics shares in Q3 2026, an estimated $70.8K.
  • 10x Genomics made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q3 2026, its #229 holding.
  • Trifecta Capital Advisors first reported a position in 10x Genomics in Q2 2025 and has held it in 6 quarters since.
  • Trifecta Capital Advisors's 10x Genomics position peaked at $338K in Q2 2025.
  • 494 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Trifecta Capital Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.